Labiana Health, S.A.

BME:LAB Stock Report

Market Cap: €55.0m

Labiana Health Past Earnings Performance

Past criteria checks 2/6

There is insufficient data on Labiana Health's performance over the last few years.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Pharmaceuticals Industry Growth4.99%
Revenue growth rate8.37%
Return on equity23.65%
Net Margin1.26%
Last Earnings Update30 Jun 2025

Recent past performance updates

Recent updates

Analysis Article Nov 27

These 4 Measures Indicate That Labiana Health (BME:LAB) Is Using Debt Extensively

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...
Analysis Article Nov 18

Labiana Health (BME:LAB) Has No Shortage Of Debt

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...
Analysis Article Jun 08

Is Labiana Health (BME:LAB) Weighed On By Its Debt Load?

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...

Revenue & Expenses Breakdown

How Labiana Health makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

BME:LAB Revenue, expenses and earnings (EUR Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 25721300
31 Mar 25701290
31 Dec 24670290
30 Sep 24670290
30 Jun 2466-1290
31 Mar 2463-3290
31 Dec 2360-4290
30 Sep 2360-7310
30 Jun 2360-10340
31 Mar 2360-9310
31 Dec 2261-9280
31 Dec 2159-2270
31 Dec 20601290
31 Dec 19511240
31 Dec 18451240

Quality Earnings: LAB has a large one-off loss of €374.0K impacting its last 12 months of financial results to 30th June, 2025.

Growing Profit Margin: LAB became profitable in the past.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: LAB has become profitable over the past 5 years.

Accelerating Growth: LAB has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: LAB has become profitable in the last year, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (15.3%).


Return on Equity

High ROE: Whilst LAB's Return on Equity (23.65%) is high, this metric is skewed due to their high level of debt.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/07/09 22:32
End of Day Share Price 2026/07/09 00:00
Earnings2025/06/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Labiana Health, S.A. is covered by 3 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Iñigo Recio PascualGVC Gaesco Valores
Alfredo Echevarria OteguiLighthouse-IEAF Servicios de Analisis
Luis Esteban ArribasLighthouse-IEAF Servicios de Analisis